- Steady as she goes, milestones recognised and passed
- Cash position, very strong and spending frugal and highly targeted
- no need to approach the market, if institutions want script, then buy on market
- Stage 2 ....results very promising
- stage 3 enrolling...............the rubber hits the road with Specificity, Sensitivity figures
- Gen 2 arising
- Focus on the FDA around the skeleton of the final submission
- Market 2025..........................and then......................
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-2
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.74 |
Change
-0.055(3.06%) |
Mkt cap ! $148.7M | |||
| Open | High | Low | Value | Volume |
| $1.78 | $1.80 | $1.73 | $122.9K | 70.02K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8000 | $1.73 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.76 | 80 | 1 |
View Market Depth
| Last trade - 15.49pm 30/06/2025 (20 minute delay) ? |
| EMV (ASX) Chart |